The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Trial of Lixisenatide in Early Parkinson’s Disease
Abstract
BACKGROUND: Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease. METHODS: In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease. Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period. The primary end point was the change from baseline in scores on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (range, 0 to 132, with higher scores indicating greater motor disability), which was assessed in patients in the on-medication state at 12 months. Secondary end points included other MDS-UPDRS subscores at 6, 12, and 14 months and doses of levodopa equivalent. RESULTS: A total of 156 persons were enrolled, with 78 assigned to each group. MDS-UPDRS part III scores at baseline were approximately 15 in both groups. At 12 months, scores on the MDS-UPDRS part III had changed by -0.04 points (indicating improvement) in the lixisenatide group and 3.04 points (indicating worsening disability) in the placebo group (difference, 3.08; 95% confidence interval, 0.86 to 5.30; P = 0.007). At 14 months, after a 2-month washout period, the mean MDS-UPDRS motor scores in the off-medication state were 17.7 (95% CI, 15.7 to 19.7) with lixisenatide and 20.6 (95% CI, 18.5 to 22.8) with placebo. Other results relative to the secondary end points did not differ substantially between the groups. Nausea occurred in 46% of participants receiving lixisenatide, and vomiting occurred in 13%. CONCLUSIONS: In participants with early Parkinson's disease, lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months in a phase 2 trial but was associated with gastrointestinal side effects. Longer and larger trials are needed to determine the effects and safety of lixisenatide in persons with Parkinson's disease. (Funded by the French Ministry of Health and others; LIXIPARK ClinicalTrials.gov number, NCT03439943.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Three clinical trials consistently describe a slowed decline in motor function when using the short-acting GLP-1 receptor agonists exenatide and lixisenatide in people with Parkinson's disease; 102-104”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [104]
In the citing paper
“The results showed that liraglutide had a modest positive effect on improving motor function and performed well in terms of safety and tolerability, although there were some manageable gastrointestinal side effects.432”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [432]
In the citing paper
“Treatment with exenatide or lixisenatide for 1 year produced a modest but positive effect on Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scores in people with recently diagnosed Parkinson’s disease (15, 53).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [53]
In the citing paper
“In Parkinson's disease, phase II trials have shown that GLP-1 RAs such as exenatide and lixisenatide improve motor activity compared to placebo,53,54 and liraglutide has shown improvements in non-motor symptoms, mobility, and quality of life.55”
From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [54]
In the citing paper
“In addition, lixisenatide slowed motor decline in a phase 2 randomized clinical trial in patients with early Parkinson disease.33”
From Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity (2025) · cites this paper as [33]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53221.x · Cited by 25,553
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536
Self-citationSystematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
JENKINSON, C., FITZPATRICK, R., PETO, V., GREENHALL, R., & HYMAN, N. (1997) · Age and Ageing · doi:10.1093/ageing/26.5.353 · Cited by 1,321
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)
Defer, G.-L., Widner, H., Mari�, R.-M., R�my, P., Levivier, M., & Conference Participants: Conference Participants: G. L. Defer, M. (. (1999) · Movement Disorders · doi:10.1002/1531-8257(199907)14:4<572::aid-mds1005>3.0.co;2-c · Cited by 865
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
Self-citationTrial of Prasinezumab in Early-Stage Parkinson’s Disease
Pagano, G., Taylor, K. I., Anzures-Cabrera, J., Marchesi, M., Simuni, T., Marek, K., Postuma, R. B., Pavese, N., Stocchi, F., Azulay, J.-P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202867 · Cited by 421
Cited by
Items 301–368 of 368
Tudosie, A. C., Marin, L.-M., Popa, S. G., & Golli, A. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083628 · Cited by 2
One‐Year Substantia Nigra R2* Changes across Parkinson's Disease Stages
Coussediere, C., Pereira, B., Devos, D., Lehéricy, S., Péran, P., Durand, E., Chassain, C., Houeto, J. L., Bénatru, I., Colin, O., et al. (2026) · Movement Disorders · doi:10.1002/mds.70331 · Cited by 2
Self-citationLi, Y., Guo, L., Yu, X., & Peng, C. (2026) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2025.31 · Cited by 1
A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders
Eijsvogel, P. P. N. M., Smits, L. M. G., Kremer, P. H. C., & Groeneveld, G. J. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70315 · Cited by 1
“48 By contrast, NLY01, a brain-penetrant pegylated analogue, did not demonstrate improvement in MDS-UPDRS part III scores in the OFF-state in a 36-week phase 2 trial including 255 patients with Parkinson’s disease (D&D Pharmatech, 2024).”
Vaidya, B., Li, Y., Kim, Y. D., Osterman, C., Revelli, J., & Zoghbi, H. Y. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.18.726024
Jernigan, J. E., Menees, K. B., & Tansey, M. G. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03858-4
“Lixisenatide, however, has completed phase 2 trials and found that 12 months of treatment with Lixisenatide in individuals with early PD resulted in decreased progression of motor disability compared to placebo [146].”
Arrar, A., Mallem, S. E., Ravier, M. A., & Costes, S. (2026) · médecine/sciences · doi:10.1051/medsci/2026065
Anti-diabetic medications to fight Parkinson's disease and dementia with Lewy bodies: a pilot study
Chmiela, T., Dulski, J., Heckman, M. G., Fang, Z. J., Wszołek, Z. K., & Wilson, J. R. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1825229 · Cited by 1
Kotecha, P., Lee, Y. A., Presti, M. F., Guo, Y., Bian, J., & Guo, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70904
“However, the evidence regarding GLP-1 RA and PD has come predominantly from studies in patients with T2D or studies assessing the progression in patients with pre-existing PD [11–14].”
Bergia, R. E., Brown, A. W., Braun, M. M., & Messina, M. J. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100689 · Cited by 1
“…myriad health benefits independent of weight loss, opening the possibility of indications for EOMs extending across diverse domains such as cardiovascular [42], renal [43], hepatic [44], neurodegenerative [45], and even behavioral reward domains unrelated to food (e.g., compulsive shopping) [46].”
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Berger, K., Karch, A., Lill, C. M., Berger, T., Mueller, U., Bartl, M., Mollenhauer, B., Fischer, B., Michels, K. B., Meyer, P. T., et al. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-026-01446-0
GLP-1 receptor agonists in obstructive sleep apnea: A propensity score-matched real-world analysis
Rai, P., Bathla, G., Praveen, N., Chen, H. A., Salim, H. A., Azzam, A. Y., Essibayi, M. A., Altschul, D. J., Dmytriw, A. A., Yedavalli, V. S., et al. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.109001
Novel treatments for Parkinson’s disease
Yin, Y., Gao, J., Zhang, K., Meng, F. D., & Feng, T. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004163
Bi, Q., Zhang, L., Zhang, J. H., (91924), X. W., Zuo, C., Zhao, S., Wang, Z. L., Zhao, Z., & Wan, H. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05635-9
Chen, Y., Zhang, Z. K., Liu, Z., Lv, T., Ye, M., Yan, J., & Zhang, M. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1858507 · Cited by 3
Unhealthy fat distribution as a sex-specific predictor of declining hippocampus insulin sensitivity
Sandforth, L., Veit, R., Machann, J., Dannecker, C., Miller, G., Jiménez‐Muñoz, M., Peter, A., von Schwartzenberg, R. J., Fritsche, A., Heni, M., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06787-2
Precision therapeutics and innovative clinical trial design in neurodegenerative diseases
Garcia, A., Delgado-Uriarte, J. C., & Cervantes‐Arriaga, A. (2026) · Revista de investigaci�n Cl�nica · doi:10.1016/j.ric.2026.100050
Mandarim‐de‐Lacerda, C. A., & Spezani, R. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.04.020
Gao, P., Wu, Y., Rumpf, S.-L., Weilin, C. H. E. N., Schaffer, P., Kolb, C., Giesbertz, P., Feng, X., Rodrigues, L. D., He, Y., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10296980/v1
Yu, T., Mai, Q., Wang, Q., Pan, M., Xiong, Y., Kuang, L., & Liu, H. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1894856
“Differences in pharmacological properties between short-acting and long-acting compounds (Drucker, 2018), variations in patient characteristics across trials (Meissner et al., 2024), and methodological heterogeneity in study design and outcome assessments may all contribute to these discrepancies.”
Zhang, S., Liu, S., Zhou, M., Wang, J., Zhang, Y., Zhong, H., & Ning, G. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06090-6
Kurowski, M., Rekiel, K., Marcinkowska, A., Ratajczyk, O., Urbanowicz, P., Iwankiewicz, S., Grzelczak, W., & mierczak, Z. K. (2026) · Medical Journal of Cell Biology · doi:10.2478/acb-2026-0005
Sitagliptin to Patients With Postprandial Hypotension Without Diabetes
Ishikawa, J., Toba, A., & Harada, K. (2026) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.70718
Wohlfeld, C., Blas, A., Woodruff, J., Frick, M., Maciejewska, N., Patel, A., Grillo, C. A., Reagan, L. P., & Fadel, J. R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.03.742612
“From this perspective, the initially surprising clinical findings that GLP-1 agonists are pharmacologically relevant in targeting disease processes in the heart, vasculature, kidneys, liver, and brain match our developing and inadequate understanding of incretin physiology [10-17].”
Topçu, U., & Oto, F. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03004-0
Chen, Y., Wang, X., Wang, J., & Ma, G. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1849318 · Cited by 1
GLP-1 and GIP class drugs have neuroprotective properties in Alzheimer’s and Parkinson’s disease
Hölscher, C. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1906426
“Two months after the trial finished, the difference was still significant, demonstrating a disease-modifying effect (Meissner et al., 2024).”
Popa, L. L., Nicolaie, A., Maștaleru, A., Socolov, Ș., Mitrea, M., Popescu, G., Schreiner, T. G., Covali, R. A., Cucu, L.-E., Dima-Cozma, L. C., et al. (2026) · Medical Sciences · doi:10.3390/medsci14040489
“Incretin or metabolic trials could similarly examine whether baseline inflammatory, metabolic or progression-rate markers identify responder groups [62].”
Adak, R., Kumar, P., Yadav, S. S., Chaudhary, S., & Datusalia, A. K. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.07.006
Redefining Parkinson’s disease: microglia and systemic immunity as gateways to early therapy
Michelucci, A., Tziortziou, M., & Grünewald, A. (2026) · Neurodegenerative Disease Management · doi:10.1080/17582024.2026.2721683
Gutierrez-Arratia, J. D., Awad, P. S., Schuh, A. F. S., & Cornejo‐Olivas, M. (2026) · Journal of Parkinson s Disease · doi:10.1177/1877718x261478730
Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review
Henriques, J. P., Rahal, J. P. S., Ribeiro, R. D. C. G., Machado, E. B. R., & Negrato, C. A. (2026) · Neurology and Clinical Neuroscience · doi:10.1002/ncn3.70165
Yi, Y., Chen, C., He, Y., Yu-zhou, S., Cheng, R., Liu, M., Liu, Z., & Zhang, X. (2026) · Medicinal Research Reviews · doi:10.1002/med.70103
Parkinson’s Disease: Current Knowledge and Future Focus
Pantazis, C. B., Sherer, T., & Riley, E. A. U. (2026) · Springer eBooks · doi:10.1007/978-3-032-31497-0_7
Dhanush, Y., Nizamuddin, N. D., Neelima, S., Kalpana, S., Arla, K. K., Ganesh, V. S., Sree, P. C., & Rohitha, C. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01961-2
Król, M., Woźniak, A., Straszewska, A., Sobantka, P., Mokrzecki, S., Mamach, A., Aleksandrowicz, K., Grodzka, Z., Meszka, M., Bełc, E., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.6208
da Silva, A. M. P., & Santos, D. H. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261485580 · Cited by 1
Parkinson’s disease—Crucial advances and on-going challenges
Söderbom, G. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.08.019
Hu, J., Zhang, Y., Wang, M., Zhang, B., Zhang, B., Ke, C., Tang, C., Xia, J., Zhao, Q., Gao, H., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00175
The Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care
Wojeck, B. S., & Nokes, B. T. (2026) · Biomedical Journal · doi:10.1016/j.bj.2026.101038
Antonini, A., Gross, R. E., Leon, M. D., Kwok, K., Foltynie, T., Höglinger, G. U., Gasser, T., Corvol, J., Pedrosa, D. J., Volkmann, J., et al. (2026) · Journal of Parkinson s Disease · doi:10.1177/1877718x261481704
Self-citationZhong, Q., Smith-Lopez, K., & Diamond, B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.01000-9
Nakagawa, Y., & Yamada, S. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06217-9
Schechter, M., Sehtman-Shachar, D. R., Fishkin, A., Mosenzon, O., Cukierman‐Yaffe, T., Sharon, R., Leibowitz, G., Arkadir, D., & Aharon‐Hananel, G. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70315 · Cited by 1
Abdelaziz, A. M., Fawzy, M. N., & Shokr, M. M. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06177-0
Tekieli, B., Cyran, W. K., Matsiusheuskaya, T., Cionżyńska, W., Machnik, K., Gaweł, B., Justkowska-Gebauer, A., Olesiński, M., Chudyba, E., & Górecki, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6110
“…disease studies support t he possibility that incretin-based therapies may be most effective during earlier stages of neurodegeneration, when neuronal reserve remains relatively preserved and metabolic abnormalities are potentially reversible (Edison et al., 2025; Meissner et al., 2024).”
Caro, I., Sargurupremraj, M., Yang, C., Akinleye, C. A., Trégouët, D., Akinyemi, R., Shigemizu, D., Coker, M. M., Akinyemi, J. O., Tiwari, H. K., et al. (2026) · Neurology Genetics · doi:10.1212/nxg.0000000000200425 · Cited by 1
“12,13,36,37 Recently, a study emulated 7 target trials based on a US nationwide database of electronic health records involving more than a million patients with T2D and no prior AD diagnosis, comparing semaglutide, a GLP-1RA drug, with 7 other anti-diabetic medications.”
Enfermedad de Parkinson: actualización clínica y nuevos enfoques diagnósticos y terapéuticos
Suárez, P. R., Sánchez-Ajofrin, J. R., & Santos‐García, D. (2026) · Medicina Clínica · doi:10.1016/j.medcli.2026.107616
Popa, E., Popa, A. E., Poroch, V., Schreiner, T. G., Slănină, A. M., Poroch, M., Hatneanu, A. M., Ungureanu, M. I., Petroaie, A. D., Bacușcă, A. I., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198738
“…progressed less in the active-treatment group, with a between-group difference of 3.08 points in MDS-UPDRS part III scores at 12 months (95% CI 0.86–5.30; p = 0.007), but gastrointestinal adverse events were common, and the durability and clinical relevance of the effect require confirmation [54].”
InfluentialVerlaufsmodifizierende Therapien der Parkinsonkrankheit: Neues zu medikamentösen Optionen
Schäfer, N., & Weise, D. (2026) · DNP – Die Neurologie & Psychiatrie · doi:10.1007/s15202-026-6784-y
Appetitzügler bei Parkinson? Zwischen Mangelernährung und GLP1-Agonisten
Ceballos-Baumann, A. (2026) · Nervenheilkunde · doi:10.1055/a-2911-3700
Future directions in Parkinson's disease pharmacotherapy
Abo‐elnour, D. E., Helal, M. M., Ahmed, B. A., Abouelmagd, M. E., Hefnawy, M. T., Alsalhi, H. K., Abdelkader, A., Al-dardery, N. M., & Alshwayyat, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27702-3.00025-x
Bariatric surgery and risk of dementia and Parkinson’s disease in patients with obesity
Shiekh, S. I., Papamargaritis, D., Goldney, J., Hernandes, G., Davies, M. J., Khunti, K., Yates, T. E., & Zaccardi, F. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02222-z
Alsharif, M., Shrebaty, O., Aloudah, M. A., Alqahtani, M., AlOubili, R. S., Ahmed, M. J., AlBani, B., & Bana, A. E. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1969490 · Cited by 1
Wang, Z., Xue, S., Zhou, X., Yuan, M., & Sun, X. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2747225
Incretin Mimetics and Alcohol‐Related Outcomes: A Structured Narrative Review
Goodyear, C., Mensah, E., Stewart-Lynch, A. L., & Covvey, J. R. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70206
“Although results were mixed, the LixiPark trial signaled a potential neuroprotective role in Parkinson's disease for lixisenatide, suggesting the benefits of incretin mimetics may extend beyond cardiometabolic health and into the realm of neurodegeneration [15].”
Xu, A., Wei, Y., Liu, E., Tong, W., Lu, A., Zhang, F., Flatt, P., Gault, V. A., Irwin, N., Hölscher, C., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118534
Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review
Chang, A. Y., & Mateen, F. J. (2026) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70547
“In a Phase II, randomized trial, lixisenatide treatment resulted in less progression of motor disability than placebo but was associated with gastrointestinal side effects [69].”
Floriano, J. F., & Menezes, M. E. (2026) · Revista Multidisciplinar do Nordeste Mineiro · doi:10.66104/pp7zdq81
Lakshmi, S. M., Singh, V., Vanangamudi, M., Taj, T., Shahin, H., Nath, R., Dutta, G., Avvari, S. K., Sridhar, S. B., Panigrahy, U. P., et al. (2026) · European Journal of Neuroscience · doi:10.1111/ejn.70718
Martinc, B., Šabović, M., Janić, M., & Lunder, M. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2754390
He, Z., Zeng, J., Wang, G., Li, Y., & Zhang, F. (2026) · MedComm · doi:10.1002/mco2.71090 · Cited by 1
“Gastrointestinal adverse effects were frequent, and further trials with larger samples and longer follow-up are needed to clarify its efficacy and safety [ 343 ].”
Repurposing existing drugs for Parkinson's disease management
Abouelmagd, M. E., Messak, M., Gadelmawla, A. F., & Kundu, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-54032-5.00007-3
The whistle-smile reflex in Parkinson's disease: an exploratory case-control study
Monteiro, M. D., Neto, E. G. D. C., Fernandez, L. L., Hilbig, A., & Rieder, C. R. D. M. (2026) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0046-1829023
Henriques, J. P., Henriques, M. J., Ribeiro, R. D. C. G., Cosentino, P. L. S., & Negrato, C. A. (2026) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-026-01275-1
“In Parkinson’s disease, phase 2 studies of exenatide and lixisenatide reported slower motor progression compared with placebo [11, 12], although nearly half of the participants treated with lix-isenatide experienced nausea [12].”
Gao, C., Shi, R., Jiang, X., Chai, H., & He, X. (2026) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2026.126237
Neurovascular-immune-clearance remodeling in brain aging
Liu, Y., Yang, R., & Chang, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1950144
Metadata
- Authors
- Meissner, W. G., Remy, P., Giordana, C., Maltête, D., Derkinderen, P., Houéto, J.-L., Anheim, M., Benatru, I., Boraud, T., Brefel-Courbon, C., Carrière, N., Catala, H., Charif, M., Colin, O., Corvol, J.-C., Damier, P., Dellapina, E., Devos, D., Drapier, S., Fabbri, M., Ferrier, V., Foubert-Samier, A., Frismand-Kryloff, S., Geny, C., Georget, A., Germain, C., Grimaldi, S., Hardy, C., Hopes, L., Krystkowiak, P., Laurens, B., Lefaucheur, R., Mariani, L.-L., Marques, A., Marse, C., Ory-Magne, F., Rigalleau, V., Salhi, H., Saubion, A., Stott, S. R. W., Thalamas, C., Thiriez, C., Tir, M., Wyse, R. K., Benard, A., & Rascol, O.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- French Clinical Research Network for Parkinson’s Disease and Movement Disorders (NS-Park/F-CRIN), France
- Université Côte d'Azur (FR)
- Inserm (FR)
- Clinical Investigation Center CIC1436 and Departments of Clinical Pharmacology and Neurosciences, Centre Expert Parkinson, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse, France
- Université de Bordeaux (FR)
- French Clinical Research Infrastructure Network (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Cure Parkinson’s, London, UK
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Service d’Information Médicale, Clinical Epidemiology Unit (USMR), CHU Bordeaux, F-33000 Bordeaux, France
- ORCID
- Meissner, Wassilios G.
- Maltête, David
- Derkinderen, Pascal
- Houéto, Jean-Luc
- Anheim, Mathieu
- Boraud, Thomas
- Carrière, Nicolas
- Colin, Olivier
- Corvol, Jean-Christophe
- Damier, Philippe
- Dellapina, Estelle
- Devos, David
- Drapier, Sophie
- Fabbri, Margherita
- Grimaldi, Stéphane
- Hopes, Lucie
- Laurens, Brice
- Lefaucheur, Romain
- Mariani, Louise-Laure
- Rigalleau, Vincent
- Stott, Simon R. W.
- Thalamas, Claire
- Thiriez, Claire
- Tir, Mélissa
- Wyse, Richard K.
- Rascol, Olivier
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-04-04
- Volume
- 390
- Issue
- 13
- Pages
- 1176-1185
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4393852482
- Cited by
- 369
- References
- 30
- Citations by year
- 2026: 125 · 2025: 160 · 2024: 83
- FWCI
- 97.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Oskar-Bordeaux (Universite de Bordeaux) (submittedVersion)
- Funders
- Cure Parkinson’s
- French Ministry of Health - PHRC-N
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- lixisenatide, Parkinson's disease, GLP-1 receptor agonists, early-stage Parkinson's disease, MDS-UPDRS III, levodopa equivalent daily dose, nausea, neuroprotection, off-medication state, washout period, subcutaneous administration, anti-inflammatory therapy, neurodegeneration, neuroinflammation
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Motor Disorders, Glucagon-Like Peptide-1 Receptor Agonists, Antiparkinson Agents, Double-Blind Method, Persons with Disabilities, Humans, Injections, Subcutaneous, Parkinson Disease, Peptides, Treatment Outcome, Disease Progression, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.